Title
Platelet aggregation and its modulation using antithrombotic agents
Authors
Nandini Srivastava1, Kaushik Ghanshyambhai Khatrani2, Bansari Yagnik Tank3, Yagnik Prafulchandra Tank4, Urvashi Bachwani5 & Kevin Ashokbhai Purohit6,*
Affiliation
1Department of Physiology, Maharshi Vashishtha Autonomous State Medical College, Basti, Uttar Pradesh, India; 2Department of Physiology, GMERS Medical College, Himmatnagar, Gujarat, India; 3Department of Microbiology, Dr. N. D. Desai Faculty of Medical Science and Research, Dharmsinh Desai University, Nadiad, Gujarat, India; 4Department of Pathology, Dr. N. D. Desai Faculty of Medical Science and Research, Dharmsinh Desai University, Nadiad, Gujarat, India; 5Department of Physiology, GMERS Medical College, Vadnagar, Gujarat, India; 6Department of Physiology, GMERS Medical College, Vadnagar, Gujarat, India; *Corresponding author
Nandini Srivastava - E - mail: vinayakasrivastava@gmail.com
Kaushik Ghanshyambhai Khatrani - E - mail: khatranik05@gmail.com
Bansari Yagnik Tank - E - mail: bansu.medico@gmail.com
Yagnik Prafulchandra Tank - E - mail: dr.yagniktank@gmail.com
Urvashi Bachwani - E - mail: urvashibachwani@gmail.com
Kevin Ashokbhai Purohit - E - mail: purohitkevin93@gmail.com
Article Type
Research Article
Date
Received March 1, 2025; Revised March 31, 2025; Accepted March 31, 2025, Published March 31, 2025
Abstract
Aggregation of platelets using three antithrombotic agents such as Ticagrelor Derivative (TD-101), Rivaroxaban Analog (RA-202) and Apixaban Variant (AV-303) were assessed. All the three agents showed dose-dependent inhibitory effects in platelet aggregation where AV-303 exhibited the strongest inhibitory activity according to light transmission aggregometry. The statistical analysis showed distinctions (p < 0.05) between groups receiving treatment and controls. This opens possibilities for medical applications in thrombotic disorder treatment. It should be noted that additional animal tests and clinical studies are needed to validate effectiveness and safety of these agents.
Keywords
Platelet aggregation, antithrombotic agents, ticagrelor derivative, rivaroxaban analog, apixaban variant, thrombosis, cardiovascular diseases, light transmission aggregometry
Citation
Srivastava et al. Bioinformation 21(3): 357-360 (2025)
Edited by
Hiroj Bagde MDS, (PhD), PGDCR, PGDHHM, PGDL, PGDM
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
